Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Drug discovery wikipedia , lookup
Orphan drug wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Prescription costs wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
Suite 305 233 E. Lancaster Ave. Ardmore, PA 19003 , Affiliate, MLHS Office: 610-642-6800 Fax: 610-642-6850 E-mail: [email protected] www.schwartzdiabetesdoc.com Diabetes, Cardio-Metabolic Newsletter Incretin Safety 2/29/16 A new international, multicenter study has found that incretin-based drugs, used to treat type 2 diabetes, are not associated with an increased risk of pancreatic cancer. Findings from this study, published in the BMJ, might help allay some of the concerns initially brought to the forefront by the U.S. Food and Drug Administration (FDA) in response to increased reporting of pancreatic cancer in patients taking incretin-based drugs vs. other oral antidiabetic agents (2.9 times higher with exenatide, 2.7 times higher with sitagliptin). Incretin-based drugs include dipeptidyl peptidase-4 (DPP-4) inhibitors (eg, linagliptin, sitagliptin, vildagliptin, saxagliptin) and glucagon-like peptide-1 receptor agonists (eg, exenatide, liraglutide). Previous studies which noted the pancreatic cancer risk (but which didn't specifically investigate it) were limited in a number of ways including, small sample sizes, low duration time follow-ups and a low number of specific incretin-based drugs. The findings of this new study suggests that when compared to sulfonylureas, incretin-based drugs are not associated with an increased risk of pancreatic cancer.In total, 972,384 patients from 6 participating sites in Canada, the U.S., and the United Kingdom, were included. In follow-ups, with the median follow-up time ranging from 1.3 to 2.8 years, 1221 out of the 972,384 were newly diagnosed as having pancreatic cancer (incidence rate 0.60 per 1000 person years). Compared with use of sulfonylureas, incretin-based drugs were not associated with an increased risk of incident pancreatic cancer (pooled adjusted hazard ratio 1.02, 95% confidence interval 0.84 to 1.23).Researchers used a nested case-control analyses methodology for each participating site. Cases of pancreatic cancer were matched with up to 20 randomly selected controls matched on sex, age, cohort entry data, duration of treated diabetes, and duration follow-up. Calculations on the crude incidence rate of pancreatic cancer were based on the Poisson distribution with 95% confidence intervals. Although incretin-based drugs have been linked with positive outcomes including lower risk of hypoglycemia, concern has arisen that their use may increase the risk of pancreatic cancer development. In a secondary analysis where DDP-4 and glucagon-like peptide-1 receptor agonists were stratified, the study also found no independent association of increased risk of pancreatic cancer in the use of incretin-based drugs by class (DPP-4 inhibitors, 1.02, 0.84 to 1.24; glucagon-like peptide-1 receptor agonists, 1.13, 0.38 to 3.38). In other secondary analyses' the results remained consistent, further disassociating the likelihood of incretinbased drugs as a cause of pancreatic cancer onset. A cumulative duration of less than one year yielded an increased but non-significant pooled hazard ratio (1.53, 0.93 to 2.51), whereas longer durations of use generated pooled hazard ratios close to or below unity (1-1.9 years, 1.07, 0.82 to 1.39; ≥2 years, 0.62, 0.36 to 1.07). The analysis of time since initiation yielded pooled hazard ratios close to the null (1-1.9 years, 1.06, 0.86 to 1.31; ≥2 years, 0.93, 0.60 to 1.45). These findings were similarly observed across each class of incretin-based drug. The patients in the study were initiated between January 2007 and June 2013, with follow-ups occurring until June 2014, meaning the longest follow-up time was 8 years. Given the latency of the cancer, the full effects of incretin-based drugs needs to be surveilled over longer durations in future studies. However the authors of the study suggest their findings do provide some reassurance to patients and clinicians with concerns of an association between incretin-based drugs and pancreatic cancer. PATIENT’S CONCERNS RAISED BY RECENT NEWSPAPER ARTICLE CAN BE MOLLIFIED BY THIS NEW ARTICLE- ALSO NOTE THE NEWSPAPER DID SAY FDA/NIH/ ADA DO NOT AGREE THAT THERE IS UNDO RISK OF CANCER WITH THESE AGENTS Feel free to call or e-mail with any questions. I’m also happy to see any patients that need extra help. Prior newsletters now available at www.schwartzdiabetesdoc.com The information presented, reviewed or discussed personal views and and by no means are intended to represent or misrepresent Please provide e-mail if you wish are tomy save paper the views of any agencies, pharmaceutical companies, product manufacturers etc. See FDA/ company literature for full prescribing receive newsletter via e-mail. information for any and all discussed or referenced medications or products.